Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Utilizing Next-Generation Sequencing (NGS) for AAV Vector ITR Integrity and Genome Sequencing

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Utilizing Next-Generation Sequencing (NGS) for AAV Vector ITR Integrity and Genome Sequencing

Next-Generation Sequencing for AAV ITR Integrity and Genome Verification

CELL & GENE | RNA | BIOLOGICS

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

Next-Generation Sequencing (NGS) provides the definitive, high-resolution data required to confirm the integrity of Adeno-Associated Virus (AAV) inverted terminal repeats (ITRs) and verify the packaged genome. This analytical method is a core component of a robust CMC data package, directly addressing regulatory expectations for product characterization. The analysis delivers comprehensive sequence verification, identifying truncations, heterogeneity, and confirming the fidelity of the entire DNA payload as a prerequisite for successful IND submissions.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

Frequently Asked Questions

    What is ITR integrity and why is it a concern for AAV vectors?

    The inverted terminal repeats (ITRs) are palindromic sequences flanking the AAV genome that are necessary for its replication and packaging into the capsid. ITR integrity is the measure of their structural completeness. Deletions or truncations within the ITRs can impair packaging efficiency and affect subsequent transgene expression, leading to a final product with reduced potency and inconsistent performance.

    How does NGS compare to older methods like Sanger sequencing for AAV analysis?

    While Sanger sequencing can verify a sequence, it is not well-suited for detecting low-frequency variants or assessing the structural integrity of the highly repetitive ITRs. NGS provides millions of parallel sequencing reads, offering deep coverage that can identify minor sequence variants, quantify truncated genome species, and confirm the complete sequence of both ITRs and the transgene cassette in a single assay.

    What specific data does an NGS analysis provide for a CMC package?

    An NGS-based analysis delivers a comprehensive data set for your vector lot, including: confirmation of the full-length vector genome sequence, identification and quantification of product-related impurities like truncated genomes, verification of ITR sequence and structure, and confirmation of the absence of plasmid backbone sequences.

    Is this type of sequencing performed under GxP conditions?

    Yes, all analytical assays intended to support regulatory filings, including NGS for vector characterization, are developed and qualified or validated in a phase-appropriate manner within our GxP-compliant environment to ensure data integrity and regulatory acceptance.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

The Requirement for Deep Sequence Verification

Traditional analytical methods for viral vectors, such as quantitative PCR (qPCR), provide accurate titer information but offer no insight into the quality of the packaged genome. A high genomic titer does not guarantee that the vector population consists of full-length, correct sequences. Recombination and replication errors during production can lead to the packaging of truncated or rearranged genomes, impacting the safety and efficacy profile of the final therapeutic.

Establishing a favorable safety profile is directly linked to the quality of the vector. Preclinical pharmacology research has shown the importance of defining vector characteristics to understand in vivo behavior and potential for adverse events (PMID: 16682254, 30112420). Without comprehensive sequence data, sponsors risk advancing a candidate with unknown heterogeneities that can compromise clinical outcomes.

AAV Genome and ITR Characterization via NGS

Our NGS-based analytical platform provides a complete profile of the DNA content within your AAV vector preparation. This approach overcomes the inherent limitations of other sequencing technologies in resolving the complex, hairpin-forming structure of the ITRs.

Our process provides clear answers to key characterization questions:

  • Is the correct, full-length genome being packaged?

  • What is the percentage of truncated vs. full-length genomes?

  • Are the ITRs intact and present in the correct orientation?

  • Are there any unintended sequences from the plasmid backbone present?

This level of detail supports a data-driven preclinical strategy, ensuring that the material used in IND-enabling toxicology studies is thoroughly characterized. Franklin Biolabs operates within a >100,000 sq ft facility, integrating these advanced analytics to support programs on an 18-24 month timeline to IND. This approach has contributed to a 100% successful IND rate for programs supported since 2019, with the Franklin Biolabs brand formally launching in 2024 to continue this legacy of scientific execution.

Our scientific team operates as a collaborative extension of our partners’ programs, applying deep, integrated expertise across the full spectrum of vector production and analytics to ensure program success.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Facility and Technology Showcase

Our integrated facilities support advanced analytics alongside preclinical and bioanalytical services. This infrastructure is designed to accelerate therapeutic programs by centralizing key development activities.

Technical Visualization: NGS Workflow for AAV Genome Verification

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities